Lihua Zhang

Lihua Zhang

Auto-generated profile, based on publicly available information

Lihua Zhang

National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
JLJingkuo Li
Jingkuo Li
LLLubi Lei
Lubi Lei
WWWei Wang
Wei Wang
WDWenbo Ding
Wenbo Ding
YYYanwu Yu
Yanwu Yu
YGYuanlin Guo
Yuanlin Guo
Background: Poor cardiovascular‐kidney‐metabolic (CKM) health is associated with premature mortality and excess morbidity in the United States. Adverse social conditions have a prominent impact on cardiometabolic diseases during the life course. We aim to examine the association between social risk profile (SRP) and CKM multimorbidity among US adults. Methods and Results: We used data from the National Health and Nutrition Examination Survey from 1999 to 2018. The definition of CKM syndrome is the coexistence of subclinical or clinical cardiovascular disease, chronic kidney disease, and metabolic disorders. We classified participants by 4 CKM stages according to the different clinical severity of different forms of CKM syndrome. We calculated the summed number of positive SRP measures, including employed, high‐income level, food secure, high education attainment, private insurance, owning a house, and married, as SRP scores and classified them into 4 levels by quartiles: low (0–2), lower‐middle (3–4), upper‐middle (5–6), and high (7–8). A total of 18 373 US adults, aged 20 to 79 years, were included in our analyses. There were 2567 (9.4%) participants with low SRP score level. Most individual SRP measures and a combined SRP score were associated with CKM stages. Compared with high SRP score level, low SRP level was associated with higher odds of having CKM stage 1 (odds ratio [OR], 1.34 [95% CI, 1.06–1.70]), CKM stage 2 (OR, 2.03 [95% CI, 1.59–2.58]), CKM stage 3 (OR, 5.28 [95% CI, 3.29–8.47]), and CKM stage 4 (OR, 5.97 [95% CI, 4.20–8.49]). Conclusions: Cumulative social disadvantage, denoted by higher SRP burden, was associated with higher odds of CKM multimorbidity, independent of demographic and lifestyle factors.

1 May 2021 in Phytomedicine
Verified
Journal Article
Open access
LZLihua Zhang
Lihua Zhang
XZXin Zheng
Xin Zheng
XBXueke Bai
Xueke Bai
QWQing Wang
Qing Wang
BCBowang Chen
Bowang Chen
JLJing Li
Jing Li
Qingfei Paidu Tang (QPT), a formula of traditional Chinese medicine, which was suggested to be able to ease symptoms in patients with Coronavirus Disease 2019 (COVID-19), has been recommended by clinical guidelines and widely used to treat COVID-19 in China. However, whether it decreases mortality remains unknown. We aimed to explore the association between QPT use and in-hospital mortality among patients hospitalized for COVID-19. A retrospective study based on a real-world database was conducted. We identified patients consecutively hospitalized with COVID-19 in 15 hospitals from a national retrospective registry in China, from January through May 2020. Data on patients’ characteristics, treatments, and outcomes were extracted from the electronic medical records. The association of QPT use with COVID-19 related mortality was evaluated using Cox proportional hazards models based on propensity score analysis. Of the 8939 patients included, 28.7% received QPT. The COVID-19 related mortality was 1.2% (95% confidence interval [CI] 0.8% to 1.7%) among the patients receiving QPT and 4.8% (95% CI 4.3% to 5.3%) among those not receiving QPT. After adjustment for patient characteristics and concomitant treatments, QPT use was associated with a relative reduction of 50% in-hospital COVID-19 related mortality (hazard ratio, 0.50; 95% CI, 0.37 to 0.66 p < 0.001). This association was consistent across subgroups by sex and age. Meanwhile, the incidences of acute liver injury (8.9% [95% CI, 7.8% to 10.1%] vs. 9.9% [95% CI, 9.2% to 10.7%]; odds ratio, 0.96 [95% CI, 0.81% to 1.14%], p = 0.658) and acute kidney injury (1.6% [95% CI, 1.2% to 2.2%] vs. 3.0% [95% CI, 2.6% to 3.5%]; odds ratio, 0.85 [95% CI, 0.62 to 1.17], p = 0.318) were comparable between patients receiving QPT and those not receiving QPT. The major study limitations included that the study was an observational study based on real-world data rather than a randomized control trial, and the quality of data could be affected by the accuracy and completeness of medical records. QPT was associated with a substantially lower risk of in-hospital mortality, without extra risk of acute liver injury or acute kidney injury among patients hospitalized with COVID-19.

3 October 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
LZLihua Zhang
Lihua Zhang
GHGuangda He
Guangda He
XHXiqian Huo
Xiqian Huo
ATAoxi Tian
Aoxi Tian
RJRunqing Ji
Runqing Ji
YPYue Peng
Yue Peng
Background: Elevated hsCRP (high‐sensitivity C‐reactive protein) level is associated with worse prognosis among patients hospitalized for heart failure. However, the prognostic value of the long‐term cumulative hsCRP remains unknown. Methods and Results: We consecutively enrolled patients hospitalized for heart failure and collected their hsCRP data at admission and 1 and 12 months after discharge. Long‐term cumulative hsCRP was evaluated using 2 approaches, cumulative hsCRP level quartiles and cumulative times of high hsCRP levels. Patients were classified into 4 groups by cumulative hsCRP level quartiles and cumulative times of high hsCRP levels (0‐ to 3‐times: number of times that hsCRP levels were higher than cutoff values at admission or 1 or 12 months), respectively. Multivariable Cox models were used to assess the association of mortality with cumulative hsCRP. A total of 1281 patients were included; the median age was 64 (interquartile range, 54–73) years, and 35.4% were women. Over a 4.8‐year (interquartile range, 4.2–5.1) follow‐up, 374 (29.2%) patients died. Elevated long‐term cumulative hsCRP level was related to higher mortality. Specifically, taking the quartile 1 as the reference, the hazard ratios (HRs) were 1.29 (95% CI, 0.92–1.81) for quartile 2, 1.62 (95% CI, 1.16–2.25) for quartile 3, and 2.38 (95% CI, 1.75–3.23) for quartile 4. Similarly, compared with the patients with 0‐times (hsCRP level lower than the cutoff values in all 3 time points) of high hsCRP level, the HRs were 1.36 for 1‐time (hsCRP level higher than the cutoff value in one of the 3 time points) (95% CI, 0.92–2.01), 1.95 for 2‐times (hsCRP levels higher than the cutoff values in 2 of the 3 time points) (95% CI, 1.34–2.82), and 2.80 for 3‐times (hsCRP levels higher than the cutoff values in the 3 time points) (95% CI, 1.97–4.00). Conclusions: Increasing long‐term cumulative hsCRP level was associated with worse outcomes in patients hospitalized for acute heart failure. Repeated hsCRP measurements could assist physicians in identifying patients with a high risk of death. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT 02878811.

18 August 2016 in Mycopathologia
Verified
Journal Article
Closed access
PDF file
CJCen Jiang
Cen Jiang
QNQi Ni
Qi Ni
DDDanfeng Dong
Danfeng Dong
LZLihua Zhang
Lihua Zhang
ZLZhen Li
Zhen Li
YPYibing Peng
Yibing Peng

1 January 2025 in Cardiorenal Medicine
Verified
Journal Article
Open access
LLLubi Lei
Lubi Lei
JLJingkuo Li
Jingkuo Li
WDWenbo Ding
Wenbo Ding
WWWei Wang
Wei Wang
YYYanwu Yu
Yanwu Yu
YGYuanlin Guo
Yuanlin Guo
Background: The American Heart Association has recently updated the Cardiovascular-Kidney-Metabolic (CKM) Health Advisory, proposing a new framework for defining, staging, and predicting CKM risk. However, the prevalence and adverse effects of the CKM stages remain insufficiently characterized. Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) (1999–2018), including 18,350 US adults aged 20–79 years. CKM syndrome encompasses subclinical or clinical cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic risk factors. The participants were categorized into 4 CKM stages based on their clinical severity. We assessed associations of CKM stages with mortality risk and life expectancy. Results: Only 12.9% of participants were classified as having CKM stage 0. The prevalence of CKM stages 1, 2, 3, and 4 was 23.1%, 53.6%, 3.6%, and 6.7%, respectively. Compared with CKM stage 0, individuals in stage 4 had a markedly higher risk of all-cause mortality (HR: 4.30, 95% CI: 2.95–6.26) and lost 15.5 (12.5–19.8) years of life at age 50 years. Sex and racial/ethnic disparities were also observed. Conclusions: A higher CKM stage was strongly associated with increased mortality and reduced life expectancy. Our findings underscore the urgent need for enhanced CKM health management, social support, and policy intervention.

2 October 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
XHXiqian Huo
Xiqian Huo
BPBoxuan Pu
Boxuan Pu
WWWei Wang
Wei Wang
YPYue Peng
Yue Peng
JLJingkuo Li
Jingkuo Li
JLJing Li
Jing Li
Importance: Sparse data exist regarding how clinician-assigned New York Heart Association (NYHA) class compares with heart failure (HF)–specific Kansas City Cardiomyopathy Questionnaire (KCCQ) in acute HF.Objective: To compare concordance between NYHA class and KCCQ overall summary score (KCCQ-OS) in acute HF and investigate associations of changes in NYHA class and KCCQ-OS with long-term outcomes.Design, Setting, and Participants: In this cohort study, patients with HF were enrolled from 52 hospitals in China between August 2016 and May 2018. Among patients with NYHA class and KCCQ-OS at admission and 1 month, levels of each scale were categorized into 4 groups from worst to best. Mild and moderate to severe discordance were defined as NYHA class and KCCQ-OS differing by 1 level or 2 or more levels, respectively. Multivariable models evaluated associations between improvements in the 2 measures and outcomes. Analysis was conducted from January to March 2023.Exposure: Changes in NYHA class and KCCQ-OS from admission to 1 month.Main Outcomes and Measures: All-cause mortality, cardiovascular death, or first HF rehospitalization.Results: A total of 2683 patients (1709 [63.7%] male; median [IQR] age, 66 [56-75] years) were included. NYHA class II, III, and IV were presented in 374 patients (13.9%), 1179 patients (44.0%), and 1130 patients (42.1%), respectively, and the median (IQR) KCCQ-OS was 44.4 (28.3-61.9). Concordance, mild discordance, and moderate to severe discordance between admission NYHA class and KCCQ-OS occurred in 954 patients (35.6%), 1203 patients (44.8%), and 526 patients (19.6%), respectively. For KCCQ-OS, kernel density overlaps were 73.6% between NYHA II and III, 63.8% between NYHA II and IV, and 88.3% between NYHA III and IV. Most patients experienced improvements in NYHA and KCCQ-OS from admission to 1 month. After adjustment, there was no significant association between improvements in NYHA class and 4-year all-cause mortality, whereas 5 or more point improvements in KCCQ-OS were independently associated with a lower risk of 4-year mortality (hazard ratio, 0.84; 95% CI, 0.74-0.96; P = .01). NYHA class and KCCQ-OS improvements were both associated with decreased risk of 1-year composite cardiovascular death or HF rehospitalization.Conclusions and Relevance: In this cohort study of acute HF, discordance between NYHA class and KCCQ was common, and KCCQ was more relevant to subsequent mortality than NYHA class.